Skip to Content

Acurx Pharmaceuticals Inc Ordinary Shares ACXP

Morningstar Rating
$2.25 +0.09 (4.17%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACXP is trading at a 735% premium.
Price
$2.26
Fair Value
$8.24
Uncertainty
Extreme
1-Star Price
$54.48
5-Star Price
$9.58
Economic Moat
Jbss
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACXP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.16
Day Range
$2.152.28
52-Week Range
$1.178.82
Bid/Ask
$2.34 / $2.69
Market Cap
$35.60 Mil
Volume/Avg
38,120 / 76,369

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
4

Valuation

Metric
ACXP
Price/Earnings (Normalized)
Price/Book Value
5.91
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ACXP
Quick Ratio
2.87
Current Ratio
2.93
Interest Coverage
Quick Ratio
ACXP

Profitability

Metric
ACXP
Return on Assets (Normalized)
−147.62%
Return on Equity (Normalized)
−229.37%
Return on Invested Capital (Normalized)
−229.37%
Return on Assets
ACXP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTglqdvkvbHxyn$586.1 Bil
VRTX
Vertex Pharmaceuticals IncDgzmyskpYpfkvz$113.7 Bil
REGN
Regeneron Pharmaceuticals IncNqvqrdlhKqypklx$108.2 Bil
MRNA
Moderna IncVlmrhgzjXdgy$50.9 Bil
ARGX
argenx SE ADRMxvgxswGxx$22.0 Bil
BNTX
BioNTech SE ADRDbnjcygrQjjrs$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncTmbyxslBzgkqkc$18.9 Bil
BMRN
Biomarin Pharmaceutical IncBdbmwmqjFnlyr$14.6 Bil
INCY
Incyte CorpZrwgfhjVnnddt$12.8 Bil
RPRX
Royalty Pharma PLC Class ARchfgkcfvDtcmdhx$12.3 Bil

Sponsor Center